Tiantan Biological's H1 Net Profit Falls 52.75% to RMB 299 Million
Tiantan Biological reported a 52.75% year-on-year decline in first-half net profit to RMB 299 million, with revenue down 16.56% to RMB 2.595 billion in 2026. The company proposed a cash dividend of RMB 1 per 10 shares, attributing the revenue drop to lower selling prices.
Tiantan Biological released its interim report for 2026. In the first half of 2026, the company recorded operating revenue of RMB 2.595 billion, down 16.56% year on year. Net profit attributable to shareholders of the listed company stood at RMB 299 million, a decrease of 52.75% from the same period last year. Basic earnings per share were RMB 0.15.
The company plans to distribute a cash dividend of RMB 1 (pre-tax) for every 10 shares to all shareholders. During the reporting period, lower selling prices led to a reduction in operating revenue.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is negative for Traditional Chinese Medicine, with intensity 60/100 and 80% confidence over a short term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.